Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Prostate Cancer · Hot Flush

Astellas Pharma

Astellas Pharma GmbH

Astellas Pharma is a pharma organization headquartered in EU. Primary therapeutic focus areas include Prostate Cancer, Hot Flush, Advanced Solid Tumors, Advanced cancer of the stomach or the gastroesophageal junction, Ga

Website Investor relations
2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP HQ
12,378 Employees
EMA registrant Type
Programs 22 Drugs 52 Patents 25 Trial starts 22 Last 12 months
Company details
Status
Public
HQ
2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP
Employees
12,378
Programs
22
Drugs
52
Patents
25
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →

Quick answer

Astellas Pharma is a pharma organization headquartered in EU. Primary therapeutic focus areas include Prostate Cancer, Hot Flush, Advanced Solid Tumors, Advanced cancer of the stomach or the gastroesophageal junction, Gastroesophageal Junction Adenocarcinoma, Gastric Cancer, Gastric Adenocarcinoma. NovaPharmaNews links 22 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (9), phase 2 (8), phase 1 (5).

Company snapshot

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas Li

  • 22 active pipeline program(s) linked via ClinicalTrials.gov.
  • 25 US patent(s) indexed to this assignee profile.
  • 22 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Astellas Pharma. Not investment advice.

Recent coverage

View all news
FDA approves Vyloy for HER2-negative gastric and GEJ cancer
High impact NewsHER2-negative gastric cancerJun 7, 2026

FDA approves Vyloy for HER2-negative gastric and GEJ cancer

FDA · HER2-negative gastric cancer · 5 min

The FDA approved zolbetuximab-clzb (Vyloy) with chemotherapy for gastric and gastroesophageal junction adenocarcinoma on October 18, 2024. Astellas says it is the first and only CLDN18.2-targeted therapy approved in the U.S. for these cancers.

Dr. Sarah Mitchell

Top assets

View drugs (52) View projects (22)

Lead pipeline drugs

Active clinical programs

  • 2215-CL-0201 Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
    Phase 3
  • 2693-CL-1303 Moderate to Severe Vasomotor Symptoms (VMS)
    Phase 3
  • 7465-CL-0301 Locally advanced or metastatic urothelial cancer
    Phase 3
  • 8951-CL-0301 Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
    Phase 3

Momentum

Proprietary activity score for Astellas Pharma.

0 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 0 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Recent activity

Latest pipeline, patent, and corporate events for Astellas Pharma.

  1. Clinical update

    8951-CL-0302 — Phase 3

  2. Clinical update

    8951-CL-0301 — Phase 3

  3. Clinical update

    2693-CL-1303 — Phase 3

  4. Clinical update

    2215-CL-5201 — Phase 1

  5. Clinical update

    2215-CL-0201 — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Astellas Pharma?

    Astellas Pharma is a pharma organization headquartered in EU. Primary therapeutic focus areas include Prostate Cancer, Hot Flush, Advanced Solid Tumors, Advanced cancer of the stomach or the gastroesophageal junction, Gastroesophageal Junction Adenocarcinoma, Gastric Cancer, Gast

  • Is Astellas Pharma publicly traded?

    Astellas Pharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Astellas Pharma develop or market?

    We link 52 drug profile(s) where Astellas Pharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/astellas-pharma-gmbh#company-drugs.

  • What are the latest developments for Astellas Pharma?

    In the last 12 months our linked public records show 22 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Astellas Pharma focus on?

    Astellas Pharma focuses on Prostate Cancer, Hot Flush, Advanced Solid Tumors based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
33
Oncology
14
Neurology
5
Cardiology
1

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.